Description: Join us as we dive into the latest high-grade discoveries at Barton Gold with CEO Alexander Scanlon. From the Eastern Gold Zone to the Western Silver Zone, explore the exciting developments and strategic insights that are shaping the future of gold and silver exploration.

Key Highlights:

Discover the dual focus on high-grade gold and silver zones. Insights into the Tolma discovery and its impact on exploration strategies. The strategic acquisition of the Wadana Gold Project and its growth potential. Innovative approaches to processing and development at Barton Gold.

Hashtags: #GoldExploration #SilverDiscovery #BartonGold #MiningInnovation

Don't forget to subscribe to Small Caps for more interviews with emerging ASX stocks! 🚀

Disclaimer: This audio is for informational purposes only and does not constitute financial advice. Please conduct your own research before investing.

📌 Articles:
Barton Gold Launches Diamond Drilling Program at Promising Tolmer Silver Prospect
Barton Gold Granted Five Additional Exploration Tenements at New Wudinna Project

🔎 More on Barton Gold:
https://smallcaps.com.au/stocks/asx-bgd/

See omnystudio.com/listener for privacy information.

In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX's lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into the company's strategic pathway, including FDA fast track designation and potential market opportunities exceeding $1.8 billion. Learn how PTX's targeted Ras pathway disruption could unlock new treatments for multiple cancers like lung, pancreatic, and biliary tumours. The conversation also covers funding strategies, the impact of government R&D incentives, and upcoming milestones that could accelerate PTX’s journey to market. Whether you're an early stage biotech investor or interested in innovative cancer therapies, this interview provides valuable insights into PTX’s potential to revolutionise oncology care. Watch till the end for key investment highlights and why Prescient Therapeutics should be on your watchlist.

📅 Timestamps:
0:02 Introduction
1:07 PTX Overview & Focus
3:14 PTX 100 Results & Safety
4:38 FDA Fast Track & Market Access
8:02 Market Opportunity & Future Potential
10:04 Development & Funding
14:03 Investment Highlights

🚨 Disclaimer: This content is for informational purposes only and does not constitute financial advice. Please conduct your own research before investing.

📌 Articles:
https://smallcaps.com.au/prescient-therapeutics-ptx-100-phase-2a-trials-outstanding-results/
https://smallcaps.com.au/prescient-therapeutics-fast-track-fda-ptx-100-t-cell-lymphoma/

🔎 More on Prescient Therapeutics:
https://smallcaps.com.au/stocks/asx-ptx/

See omnystudio.com/listener for privacy information.

In this exclusive interview, Jess Fertig welcomes Andrew Vigar, Chairman of Terra Uranium (ASX: T92.ASX), to discuss the company's exciting strategic moves into critical minerals like tungsten, tin, molybdenum, and bismuth. Discover how Terra Uranium is leveraging innovative technologies such as optical sorting to unlock the potential of the Glen Eden project—the largest undeveloped tungsten asset in NSW—and how recent capital raises are funding exploration efforts. Andrew breaks down the significance of the projects, their scale, and the company's vision to create a globally significant resource portfolio in Australia. Plus, insights into government support, environmental advantages of modern processing, and the company's long-term growth strategy. Stay tuned for key investment highlights and why Terra Uranium could be a major player in the critical minerals space.

Don't forget to subscribe to Small Caps for more interviews with emerging ASX stocks! 🚀

*Disclaimer: This video is for informational purposes only and does not constitute financial advice. Please conduct your own research before investing.*

📌 Articles:
https://smallcaps.com.au/terra-uranium-to-acquire-undeveloped-tungsten-tin-molybdenum-project-in-nsw/
https://smallcaps.com.au/terra-uranium-drilling-campaigns-spire-horizon-positive-survey-data/

🔎 More on Terra Uranium:
https://smallcaps.com.au/stocks/asx-T92/

See omnystudio.com/listener for privacy information.